ITGB4 showed effectiveness in discriminating CRC patients from HCs by the ROC curve, with an AUC of 0.761 (95% confidence interval: 0.685–0.837; p < 0.0001; Figure 1B,C). Here, ITGB4 is linked to colorectal carcinoma.